CuraGen Corporation
(Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) today
announced the Southwest Oncology Group, a national clinical trials
cooperative group, has just opened a Phase II clinical trial to test the
effects of a new investigational agent on aggressive B-cell lymphoma. The
agent, PXD101, will be evaluated in patients whose previous treatment
regimen did not work or whose cancer returned after treatment. The trial,
also known as S0520, is sponsored by the National Cancer Institute (NCI)
under a Clinical Trials Agreement signed with CuraGen Corporation.
PXD101 is designed to inhibit histone deacetylase (HDAC). Histones are
a class of proteins around which DNA is wrapped. The tightness of the
wrapping controls the activity of the genes on the DNA. HDAC is an enzyme
that changes the way histones bind to the genes. Laboratory studies suggest
that drugs such as PXD101 can act on histones to kill cancer cells or
prevent them from growing.
The purpose of the trial is to evaluate how B-cell lymphoma cells
respond to the new agent, how patients tolerate the treatment and how long
patients can live with the treatment without the disease becoming worse.
Based on published preliminary data, study leaders are particularly
interested in whether PXD101 will enhance expression of immune-mediating
molecules on the tumor cells' surface and thereby increase the immune
system's ability to target the lymphoma.
Study leaders would like to enroll up to 40 patients with refractory
aggressive diffuse large, high-grade Burkitt's or Burkitt's-like or primary
mediastinal B-cell lymphoma for the trial. So far, 81 Southwest Oncology
Group institutions are participating in the trial.
Patients enrolled in the trial will receive PXD101 intravenously in
three-week cycles. The primary goal of this study is to evaluate the
response rate for patients receiving treatment with PXD101. In addition,
correlative studies will be performed on some of the patients to assess
histone acetylation and potential biomarkers.
"HDAC inhibitors are believed to target DNA and lead to reactivating
genes that suppress tumors. Since this may slow the growth and survival of
tumor cells, we are very interested in investigating PXD101 to assess its
potential benefit for patients with B-Cell lymphoma," said Steven H.
Bernstein, M.D., the study coordinator.
Dr. Bernstein is Associate Professor of Medicine and Co-director of the
Lymphoma Biology Program at the James P. Wilmot Cancer Center at the
University of Rochester School of Medicine in Rochester, N.Y.
About Aggressive B-cell Lymphomas
B-cell lymphomas are a type of non-Hodgkin's lymphoma (NHL) that
account for approximately 85 percent of the approximately 56,000 new cases
of NHL diagnosed annually in the U.S. B-cell lymphomas are specifically
characterized in subtypes by numerous chemical and genetic attributes.
These lymphomas are also generally classified into two subsets used to
define outcome including indolent, or slow-growing, and aggressive, or
rapidly growing. Over the past 30 years, there has been a steady increase
in the incidence of NHL, with a greater number of cases diagnosed in men
than women, at a median age of older than 50 years. While the exact causes
of B-cell lymphomas are unknown, there are several environmental factors
and genetic abnormalities that are believed to play a role. Aggressive
B-cell lymphomas are typically treated with radiotherapy, chemotherapy
regimens, biologics, or a combination of treatments. The overall five-year
survival rate for patients with NHL is approximately 60 percent, although
response rates and survival vary greatly based on the grade and type of
B-cell lymphoma being treated.
About PXD101
PXD101 is a promising small molecule HDAC inhibitor being investigated
for its role in the treatment of a wide range of solid and hematologic
malignancies either as a single-agent, or in combination with other active
anti-cancer agents, including 5-fluorouracil (5-FU), carboplatin,
paclitaxel, cis-retinoic acid and Velcade(r) (bortezomib) for Injection.
HDAC inhibitors represent a new mechanistic class of anti-cancer
therapeutics that target HDAC enzymes and have been shown to: arrest growth
of cancer cells (including drug resistant subtypes); induce apoptosis, or
programmed cell death; promote differentiation; inhibit angiogenesis; and
sensitize cancer cells to overcome drug resistance when used in combination
with other anti-cancer agents.
PXD101 is currently being evaluated in multiple clinical trials as a
potential treatment for multiple myeloma, T-cell lymphoma, and colorectal
and ovarian cancers, either alone or in combination with anti-cancer
therapies. In August 2004, CuraGen signed a Clinical Trials Agreement with
the NCI under which the NCI will sponsor several clinical trials to
investigate PXD101 for the treatment of various cancers, both as a
single-agent and in combination chemotherapy regimens. In May 2005,
TopoTarget announced the signing of a Cooperative Research and Development
Agreement (CRADA) with the NCI to conduct pre-clinical and non-clinical
studies on PXD101 in order to better understand its anti-tumor activity and
to provide supporting information for clinical trials.
About CuraGen
CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company
developing diverse approaches, including novel protein, antibody, and small
molecule therapeutics, that aim to offer hope for patients with cancer,
inflammatory diseases, and diabetes. CuraGen's strategic alliances have
resulted in a deep pipeline of potential therapeutics that is being
developed by the Company's experienced research and development teams. By
leveraging the drug development strengths cultivated over the years,
CuraGen expects to make a difference in the lives of patients by bringing
forward promising therapeutics that address unmet medical needs. To further
capitalize on CuraGen's extensive research and development expertise,
CuraGen founded a majority-owned subsidiary, 454 Life Sciences, which has
developed and is commercializing advanced technologies for the sequencing
of DNA. CuraGen and 454 Life Sciences are headquartered in Branford,
Connecticut. For additional information on the companies please visit
curagen and 454lifesciences.
About TopoTarget
TopoTarget (Cse: TOPO) is a fully integrated biopharmaceutical company,
headquartered in Denmark and with subsidiaries in the UK and Germany, and
dedicated to finding ''Answers for Cancer'' and developing improved cancer
therapies. TopoTarget is founded and run by clinical cancer specialists and
combines years of hands-on clinical experience with in-depth understanding
of the molecular mechanisms of cancer. Focus lies on key cancer enzyme
regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a
strong development foundation of proprietary, highly predictive cancer
models has been built. TopoTarget has a broad portfolio of small molecule
preclinical drug candidates and eight drugs are in clinical development,
consisting of both novel anti-cancer therapeutics and new cancer
indications for existing drugs. TopoTarget's first product, Savene(TM) has
been granted marketing approval by EMEA. In addition to organic growth,
TopoTarget consistently looks for opportunities to strengthen and expand
its activities through acquisitions and in-licensing. For more information,
please refer to topotarget.
About the Southwest Oncology Group
The Southwest Oncology Group is one of the largest cancer clinical
trials cooperative research groups in the United States. The Group is a
network of more than 5,000 physician-researchers located at nearly 550
institutions. In addition to their regular medical practices, Group
investigators work together on clinical trials funded by the National
Cancer Institute, part of the National Institutes of Health, to prevent and
treat cancer in adults. Among the Group's institutions are 17 of the NCI's
61 designated cancer centers. The Group enrolls nearly 7,200 patients each
year and has about 120 clinical trials underway at any given time. The
Southwest Oncology Group Headquarters Office is at the University of
Michigan in Ann Arbor, Mich., the Operations Office is in San Antonio,
Texas, and the Statistical Center is in Seattle, Wash.
Safe Harbor
This press release may contain forward-looking statements including
statements about the expected benefits of PXD101 and the expected timing of
our clinical trials. We caution investors that there can be no assurance
that actual results or business conditions will not differ materially from
those projected or suggested in such forward-looking statements as a result
of various factors, including, but not limited to, the following: the risk
that any one or more of the PXD101 or any other CuraGen drug development
program will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrollment issues or based on new information
from nonclinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; CuraGen's history of
incurring losses and the uncertainty of achieving profitability; CuraGen's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against CuraGen's products, processes and
technologies; the ability to protect CuraGen's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure. Please refer to CuraGen's annual and quarterly reports
on Forms 10-K and 10-Q for a complete description of these risks. CuraGen
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.
CuraGen Corporation
curagen